Medtronic faces currency exchange rate risk from unhedged foreign currency exposures, potentially impacting earnings and cash flows. Interest rate risk exists on investments and borrowings. Litigation risk, including product liability (hernia mesh, diabetes pump), intellectual property disputes, and governmental proceedings, could result in significant expenses. Economic factors like competition, pricing pressure, reimbursement challenges, and supply chain disruptions pose ongoing risks. The company's tax position is uncertain, with potential future tax liabilities from ongoing audits and the global minimum tax.

Read More

Medtronic's net sales increased in most segments, driven by strong growth in TAVR, Cardiac Rhythm Management, Cardiac Surgery, Neuromodulation, Spine, Biologics, and Neurosurgery. The company has a strong financial position with substantial cash and investments, a credit facility, and commercial paper programs. Acquisitions and share repurchases are ongoing strategies to enhance shareholder value. Continued product development and regulatory approvals present potential for future revenue growth.

Read More